Obesity drug tirzepatide approval in China strengthens market position amid GLP-1 agonist competition: GlobalData Benemaes benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisks diabetes therapy semaglutide (Wegovy) in June 2024 Eli Lillys tirzepatide (Mounjaro) has recently been approved by the National Medical Products Administration (NMPA) for treating obesity
HEDISON to secure a valued position in dermatology clinics and prestigious beauty salons worldwide
The drug does not undergo hepatic phase I or phase II metabolism
Then, I realized I was a) using Paleo as a tool for disordered eating and had become so orthorexic, that 2) Id given myself atypical anorexia and a myriad of health ailments
Wakabayashi T, Yamaguchi K, Matsui K, Sano T, Kubota T, Hashimoto T, Mano A, Yamada K, Matsuo Y, Kubota N, Kadowaki T, Iwatsubo T (2019) Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimers disease
Hypersensitivity is also rare